These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 15267190)

  • 61. A controlled trial to compare the therapeutic effects of dapsone in combination with daily or once-monthly rifampin in patients with lepromatous leprosy.
    Opromolla DV; Tonello CJ; McDougall AC; Yawalkar SJ
    Int J Lepr Other Mycobact Dis; 1981 Dec; 49(4):393-7. PubMed ID: 7042603
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Evaluation of anti-bacterial activity of Rifapentine, Clarithromycin, Minocycline, Moxifloxacin, Ofloxacin and their combinations in Murine Model of Rifampicin Resistant Leprosy.
    Joseph P; Ponnaiya J; Das M; Chaitanya VS; Arumugam S; Ebenezer M
    Indian J Lepr; 2016; 88(3):147-58. PubMed ID: 30207440
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A study on the impact of FD-MDT on 200 leprosy patients.
    Vara N; Marfatiya Y
    Indian J Lepr; 2005; 77(3):217-27. PubMed ID: 16353520
    [TBL] [Abstract][Full Text] [Related]  

  • 64. International open trial of uniform multi-drug therapy regimen for 6 months for all types of leprosy patients: rationale, design and preliminary results.
    Kroger A; Pannikar V; Htoon MT; Jamesh A; Katoch K; Krishnamurthy P; Ramalingam K; Jianping S; Jadhav V; Gupte MD; Manickam P
    Trop Med Int Health; 2008 May; 13(5):594-602. PubMed ID: 18346026
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A study on the effectiveness and safety of the WHO/MDT regimen in the northeast of Thailand; a prospective study, 1984-1996.
    Dasananjali K; Schreuder PA; Pirayavaraporn C
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):28-36. PubMed ID: 9207751
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A comparative clinical trial in multibacillary leprosy with long-term relapse rates of four different multidrug regimens.
    Fajardo TT; Villahermosa L; Pardillo FE; Abalos RM; Burgos J; Dela Cruz E; Gelber RH
    Am J Trop Med Hyg; 2009 Aug; 81(2):330-4. PubMed ID: 19635893
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Correlation between dose/plasma concentration and assessment of hepatic and renal changes in Wistar rats treated with the ROM scheme].
    Malfará WR; Uyemura SA; Queiroz RH
    Rev Soc Bras Med Trop; 2005; 38(2):167-72. PubMed ID: 15821793
    [TBL] [Abstract][Full Text] [Related]  

  • 68. New lesions after MDT in PB and MB leprosy: a report of 28 cases.
    Kar HK; Sharma P
    Indian J Lepr; 2008; 80(3):247-55. PubMed ID: 19432355
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Leprosy situation in endemic states of India and prospects of elimination of the disease.
    Subramanian M; Showkath Ali MK; Thorat DM; Muthukumar M; Sathiskumar E; Ramadoss C; Ali Khan M
    Indian J Lepr; 2003; 75(4):335-45. PubMed ID: 15242272
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Population screening and mass chemoprophylaxis in Kiribati.
    Daulako EC
    Int J Lepr Other Mycobact Dis; 1999 Dec; 67(4 Suppl):S23-5. PubMed ID: 10700933
    [No Abstract]   [Full Text] [Related]  

  • 71. Multibacillary leprosy: follow up observations on 19 patients treated with 12 monthly doses of rifampicin, ofloxacin and minocycline therapy in Agra.
    Kumar A; Girdhar BK
    Indian J Dermatol Venereol Leprol; 2014; 80(2):156-9. PubMed ID: 24685858
    [No Abstract]   [Full Text] [Related]  

  • 72. Trials of daily, long-term minocycline and rifampin or clarithromycin and rifampin in the treatment of borderline lepromatous and lepromatous leprosy.
    Rea TH
    Int J Lepr Other Mycobact Dis; 2000 Jun; 68(2):129-35. PubMed ID: 11036492
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Population screening and chemoprophylaxis for household contacts of leprosy patients in the Republic of the Marshall Islands.
    Tin K
    Int J Lepr Other Mycobact Dis; 1999 Dec; 67(4 Suppl):S26-9. PubMed ID: 10700934
    [No Abstract]   [Full Text] [Related]  

  • 74. Relapse rates and a 10-year follow-up of a 6-week quadruple drug regimen for multibacillary leprosy.
    Pattyn S; Grillone S
    Lepr Rev; 2002 Sep; 73(3):245-7. PubMed ID: 12449889
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical and histopathological evaluation of the effect of addition of immunotherapy with Mw vaccine to standard chemotherapy in borderline leprosy.
    Kamal R; Natrajan M; Katoch K; Arora M
    Indian J Lepr; 2012; 84(4):287-306. PubMed ID: 23720894
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Monthly rifampicin, ofloxacin, and minocycline therapy for generalized and localized granuloma annulare.
    Garg S; Baveja S
    Indian J Dermatol Venereol Leprol; 2015; 81(1):35-9. PubMed ID: 25566894
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Fixed duration MDT in paucibacillary leprosy (classical and modified).
    Nadkarni NJ; Grugni A; Kini MS
    Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):25-8. PubMed ID: 8326177
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Nasal mucosa and skin of smear-positive leprosy patients after 24 months of fixed duration MDT: histopathological and microbiological study.
    Ebenezer GJ; Job A; Abraham S; Arunthathi S; Rao PS; Job CK
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):292-7. PubMed ID: 10575409
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice.
    Ji B; Perani EG; Petinom C; Grosset JH
    Antimicrob Agents Chemother; 1996 Feb; 40(2):393-9. PubMed ID: 8834886
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Short term chemotherapy of paucibacillary leprosy.
    Dhir R; Guha PK; Singh G
    Indian J Lepr; 1986; 58(4):549-54. PubMed ID: 3572096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.